Constellium has raised its adjusted EBITDA guidance for 2026 to between $980 million and $1.02 billion, driven by structural margin improvements and strong segment performance. The company has also achieved its 2028 targets ahead of schedule, supported by a pass-through business model and strong operating leverage that enable high incremental margins. Despite risks from potential tariff reductions and normalization of Midwestern Premium, Constellium's resilient EBITDA history and ongoing capacity expansions mitigate these concerns. The company continues to support growth and valuation upside through share repurchases, disciplined capital allocation, and investments in new recycling and casting facilities.
Constellium's financial outlook is detailed as of Oct 02, 2026 00:02 WIB. For readers following the Basic Materials sector, here is Pluang's market snapshot as of that time: out of 38 priced US stocks, 7 rose and 31 fell. Notable movers include ICL at USD 4.94 with a 1-day change of -1.59%, APD at USD 272.15 down 1.54%, and CF at USD 113.51 down 1.50% with Pluang order activity showing 0% Sell / 100% Buy. The most notable figure is the breadth showing a majority of stocks declining today.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
